Glycyx
Company Details
Status: Private
Employees: 1-10
Location:
San Francisco, California, United States
Type:
sample
Technology:
About: Glycyx is at the forefront of cancer treatment by addressing the overlooked issue of opioids reducing immunotherapy effectiveness. As a biotech firm entering Phase 2, we are pioneering a novel therapy to ensure pain management doesn't compromise anti-PD1/PD-L1 treatments. Our goal: to greatly enhance survival and quality of life for cancer patients globally.
The integration of opioids into cancer care, vital for managing the severe pain experienced by patients, inadvertently presents a significant challenge in oncological treatment effectiveness. Recent scientific insights reveal that opioids, beyond their analgesic properties, undermine the efficacy of immune checkpoint inhibitors (ICIs) — a cornerstone in modern cancer therapy known for their potential to significantly improve survival in various solid tumors. This interaction leads to what is identified as Opioid-Induced Immunotherapy Failure (OIIF), a condition where the immunosuppressive and pro-angiogenic effects of opioids diminish the body's immune response to cancer cells, thereby compromising the effectiveness of ICIs.
Glycyx proposes a groundbreaking solution to this critical challenge with the development of a small molecule peripherally restricted opioid antagonist designed to counteract the negative effects of opioids on immune checkpoint inhibitor therapies without compromising pain relief. This novel drug, intended as a combination therapy with ICIs, axelopran will:
• Reverse Opioid-Induced Immunosuppression
• Enable Re-challenge in Treatment-Resistant Cancers
• Robust Safety Credentials Established in Earlier Studies
• Demonstrated Efficacy in Preclinical Studies
• Phase 2 Ready, CMC Complete, Clinical Supply Built through Phase 3
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Glycyx | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.